Inflammatory muscle diseases can be divided into three broad categories: idiopathic inflammatory myopathy (IIM), pathogen associated myositis, and drug-treatment associated myositis. Over the last several decades, advanced medical technologies and new discoveries has added the new concepts into the field. For example, the classification of IIM has been evolved by the association of myositis specific antibodies and their specific clinicopathological and transcriptomic features. In addition, growing knowledge of underlying pathophysiological mechanism of IIM further shapes the treatment regimen among the subtypes. Likewise, new pathogen and new drug-treatment associated myositis has been emerged e.g. SARS-CoV-2 associated myositis and checkpoint inhibitor associated myositis.
This research topic aims to highlight and provide further understanding of pathophysiological mechanisms, specific antibodies/biomarkers analysis and their limitations, clinical presentation and diagnostic approaches, muscle imaging, and other relevant investigations. The scope of inflammatory muscle diseases include four major subtypes of IIM (dermatomyositis, immune mediated necrotizing myopathy, antisynthetase syndrome and inclusion body myositis), less common IIM (which include but may not limit to sporadic late onset nemaline myopathy, granulomatous myositis, and eosinophilic myositis), and newly emerging pathogen and drug-treatment related myositis.
Areas of interest include, but are not limited to the following:
- Diagnostic approaches, clinical courses, and management
- Pathology and pathophysiology perspectives
- Antibodies and biomarkers
We welcome translational and clinical articles including: Original Research, Systematic Review, Reviews, Mini reviews, Case Reports, and Perspectives.
Inflammatory muscle diseases can be divided into three broad categories: idiopathic inflammatory myopathy (IIM), pathogen associated myositis, and drug-treatment associated myositis. Over the last several decades, advanced medical technologies and new discoveries has added the new concepts into the field. For example, the classification of IIM has been evolved by the association of myositis specific antibodies and their specific clinicopathological and transcriptomic features. In addition, growing knowledge of underlying pathophysiological mechanism of IIM further shapes the treatment regimen among the subtypes. Likewise, new pathogen and new drug-treatment associated myositis has been emerged e.g. SARS-CoV-2 associated myositis and checkpoint inhibitor associated myositis.
This research topic aims to highlight and provide further understanding of pathophysiological mechanisms, specific antibodies/biomarkers analysis and their limitations, clinical presentation and diagnostic approaches, muscle imaging, and other relevant investigations. The scope of inflammatory muscle diseases include four major subtypes of IIM (dermatomyositis, immune mediated necrotizing myopathy, antisynthetase syndrome and inclusion body myositis), less common IIM (which include but may not limit to sporadic late onset nemaline myopathy, granulomatous myositis, and eosinophilic myositis), and newly emerging pathogen and drug-treatment related myositis.
Areas of interest include, but are not limited to the following:
- Diagnostic approaches, clinical courses, and management
- Pathology and pathophysiology perspectives
- Antibodies and biomarkers
We welcome translational and clinical articles including: Original Research, Systematic Review, Reviews, Mini reviews, Case Reports, and Perspectives.